STAT3 and cancer: This combinatorial approach aimed to block the IAPs that are overexpressed in cancer, mitigate BV6-induced side effects, and suppress STAT3 expression, which has been shown in vitro to induce anticancer responses in breast cancer, colorectal cancer, and melanoma cell lines.